FDBusiness.com

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

 Breaking News
  • Lactalis Expands in Infant Nutrition With €740 Million Acquisition Lactalis Group, the international dairy group based in Laval, France, is acquiring the Nutritional business of Aspen Pharmacare for €739.8 million (R12.9 billion). The business being acquired supplies a wide range of infant nutritional and growing-up milk products across both the premium and value segments. It manufactures and markets well established quality brands, including S-26, [...]...
  • Thatchers Cider to Invest £14 Million in New Cider Mill Thatchers Cider, the family owned English cider producer, is to invest £14 million in a new cider mill at its Myrtle Farm site in Somerset to meet growing demand for its products. The company has applied for planning permission and, if granted, the new mill would come on stream in 2019. “This investment is about our [...]...
  • Coca-Cola Great Britain Teams Up With Premier League Premier League and Coca-Cola Great Britain have announced a new three-and-a-half-year partnership, starting in January 2019. It is the first sponsorship Coca-Cola Great Britain will activate across multiple brands within its portfolio, showcasing a range of drinks including sparkling soft drinks, water and fruit-based drinks, with low and no-sugar options. The partnership will see Coca-Cola work [...]...
  • Barry Callebaut Completes $30 Million Capacity Expansion in North America Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa products, has announced the completion of several expansion investments in three of its North American facilities located in St Hyacinthe, Quebec; Chatham, Ontario; and St Albans, Vermont. The investments amount to close to US$30 million and are in line with previously announced plans. Recent investments [...]...
  • Strong First Half From Hilton Food Group Hilton Food Group, the UK-based leading specialist international food packing business, has reported a 25.0% increase in turnover to £863.6 million and by 24.5% on a constant currency basis for the 28 weeks to 15 July 2018. Volumes increased by 12.7% reflecting growth in the UK, Ireland and Australia. Operating profit for the first half [...]...

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients

Enzymotec Presents Clinical Trials Strategy For its Infant Nutrition Lipid Based Ingredients
September 11
09:01 2012

Biotech company Enzymotec has reported that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results. This plan is part of a comprehensive business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA).Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months. These large-scale clinical research trials were conducted on newborn term infants in several institutes worldwide. Clinical results already have been presented at leading professional conferences.

One of the studies recently completed was a controlled clinical trial on InFat®. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. It enables easy digestion and optimized uptake of calcium, fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture between AAK and Enzymotec. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants’ well-being. It was conducted by Professor Chen Yu-Ming, the principle investigator at SunYat-Sen Universityand in collaboration with Enzymotec.

“The clinical trials plan represents Enzymotec’s ongoing commitment to explore the special characteristics of human milk and demonstrate its lipid-based ingredients’ health benefits on various infant populations,” says Yael Lifshitz, PhD, Director of R&D, of Enzymotec Infant Nutrition. “We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development—a percentage considered among the highest in the industry.”

About Author

mike

mike

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 25, 2018PPMA Show 2018
  • September 27, 2018Int'l Fruit Show (eurofruit)
  • September 30, 2018Trade Fair for Butchers, Caterers and Meat Industry (Meat Expo)
  • October 1, 2018Poznan International Fair
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements